Research Article
Comparison Effects of Propofol-Dexmedetomidine versus Propofol-Remifentanil for Endoscopic Ultrasonography: A Prospective Randomized Comparative Trial
Table 2
Respiratory and hemodynamic adverse events and medication.
| | PD () | PR () | value |
| | Respiratory adverse events | | | | | Chin lift/jaw thrust | 3 (3.2%) | 3 (3.2%) | 1.000 | | Mask ventilation | 0 | 0 | | | Tracheal intubation | 0 | 0 | | | Hemodynamic adverse events | | | | | Hypotension | 8 (8.5%) | 5 (5.4%) | 0.567 | | Bradycardia | 2 (2.1%) | 1 (1.1%) | 1.000 | | Usage of vasoactive drugs | 1 (1.1%) | 1 (1.1%) | 1.000 | | Usage of glycopyrrolate | 1 (2.1%) | 0 | 1.000 | | Dosage of dexmedetomidine, μg | | | | | Dosage of remifentanil, μg | | | | | Additional propofol | | | | | Patients, (%) | 26 (27.7%) | 20 (21.5%) | 0.396 | | Dosage, mg | | | 0.183 | | Total dosage of propofol, mg | | | 0.104 |
|
|
Values are presented as frequencies (percentages). PD group: propofol-dexmedetomidine group; PR group: propofol-remifentanil group.
|
